Acute lymphoblastic leukemia

February 10, 2023

Trial Results: ASH Highlights Practice-Changing Results for B-Lineage Acute Lymphoblastic Leukemia

The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
December 20, 2022

Re-Opened Trial: EA9152 for T-cell or B-cell Acute Lymphoblastic Leukemia

This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
October 13, 2022

Trial Spotlight: Yishai Ofran on the EA9181 Study for Acute Lymphoblastic Leukemia

This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
June 21, 2022

Now Enrolling: EA9213 for T-Cell Acute Lymphoblastic Leukemia

This single-arm phase II study aims to rid patients of residual disease following initial treatment
September 30, 2021

Now Enrolling: Phase II of EA9152 for Acute Lymphoblastic Leukemia

This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL